肺结核合并乙肝病毒无症状携带者的抗结核治疗

Treatment of Antituberculous Agents in the Patients with Pulmonary Tuberculosis and Asymptomatic Carrier of HBV

目的 探讨肺结核合并乙肝病毒无症状携带者（ASC）抗结核治疗对肝功能的影响。方法 采用2HRZ／4－7HRE抗结核治疗，用生化自动分析仪观察肝功能改变。结果 ALT和AST轻度升高12／67，STB轻度升高2／67。经保肝治疗及密切监测肝功能改变后，大多数顺利地完成了抗结核治疗。结论 经密切监护，肺结核合并ASC者的抗结核治疗是安全的。

Objective To probe hepatic functional influence on the patient with pulmonary tuberculosis and asymptomatic carrier (ASC) of HBV in the therapy of antituberculous agents. Methods Observe hepatic functional changes of those patients by means of biochemical automatic analystor in the therapy of 2HRSZ/4 7HRE. Results The slight lifted value of ALT and AST was observed in 12/67 cases. The slight increased value of serum total bilirubin (STB) was observed in 2/67 cases. Taken protective hepatic functional medicine and monitored closely hepatic function most of those patients received smoothly antituberculous agents. Conclusion Monitored closely hepatic function is safe that the patients with pulmonary tuberculosis and ASC of HBV receives the therapy of 2HRSZ/4 7HRE.